Related Experiment Video

Updated: May 16, 2025

Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head
05:55

Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head

Published on: September 27, 2024

435

The effect of antenatal steroids on metabolic bone disease of prematurity

Sara Erol1, Mustafa Senol Akin1, Nihan Hilal Hosagasi1

  • 1Department of Pediatrics, Division of Neonatology, Ankara Bilkent City Hospital, Ankara, Türkiye.

Journal of Pediatric Endocrinology & Metabolism : JPEM
|May 14, 2025
PubMed

Insights

Antenatal steroid administration did not affect metabolic bone disease in preterm infants. Lower birth weight, not steroid exposure, was the primary risk factor for this condition.

Area of Science:

  • Neonatal care
  • Pediatric endocrinology
  • Perinatology

Background:

  • Metabolic bone disease (MBD) is a concern in preterm infants.
  • Antenatal steroids are used to reduce preterm infant mortality and morbidity.
  • The impact of antenatal steroids on MBD development requires further investigation.

Purpose of the Study:

  • To assess the effect of antenatal steroid administration on the development of MBD in preterm infants.
  • To identify risk factors for MBD in this population.

Main Methods:

  • Retrospective study in a Level III NICU (Oct 2020 - Dec 2023).
  • Included 173 infants born before 32 weeks gestation.
  • MBD diagnosed at 4 weeks based on serum phosphorus and alkaline phosphatase levels.

Main Results:

  • 15% (26/173) of infants developed MBD.
  • Lower birth weight was the only independent risk factor for MBD.
  • Antenatal steroid exposure did not significantly impact MBD diagnosis.

Conclusions:

  • Antenatal steroids do not appear to influence MBD diagnosis at 4 weeks.
  • Birth weight is a critical factor in MBD risk.
  • Further research may explore other potential interventions for MBD prevention.
Abstract

Keywords:
antenatal corticosteroidmetabolic bone diseaseprematurity

More Related Videos

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

11.2K
Author Spotlight: Studying the Impact of Maternal Dietary Deficiencies on Long-Term Offspring Health Outcomes03:19

Author Spotlight: Studying the Impact of Maternal Dietary Deficiencies on Long-Term Offspring Health Outcomes

Published on: June 28, 2024

327

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.3K
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
3.4K
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
2.5K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
114
Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
20.3K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
2.8K